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Abstract
Background: New drugs often substitute others cheaper and with a risk-benefit balance better established. Our
aim was to analyse the diffusion of new drugs during the first months of use, examining the differences between
family physicians and specialists.
Methods: Prescription data were obtained of cefditoren, duloxetine, etoricoxib, ezetimibe, levocetirizine,
olmesartan, pregabalin and tiotropium 36 months after their launching. We obtained the monthly number of
prescriptions per doctor and the number prescribers of each drug by specialty.
After discarding those with less than 10 prescriptions during this period, physicians were defined as adopters if the
number of prescriptions was over the 25th percentile for each drug and level (primary or secondary care). The
diffusion of each drug was studied by determining the number of adopter family physicians throughout the study
period. Among the group of adopters, we compared the month of the first prescription by family physicians to
that of other specialists using the Kaplan-Meier method.
Results: The adoption of the drugs in primary care follows an exponential diffusion curve that reaches a plateau at
month 6 to 23. Tiotropium was the most rapidly and widely adopted drug. Cefditoren spread at a slower rate and
was the least adopted. The diffusion of etoricoxib was initially slowed down due to administrative requirements for
its prescription. The median time of adoption in the case of family physicians was 4-6 months. For each of the
drugs, physicians of a specialty other than family physicians adopted it first.
Conclusions: The number of adopters of a new drug increases quickly in the first months and reaches a plateau.
The number of adopter family physicians varies considerably for different drugs. The adoption of new drugs is
faster in specialists. The time of adoption should be considered to promote rational prescribing by providing timely
information about new drugs and independent medical education.
Keywords: Diffusion of innovation, Drug prescriptions, Drug utilization, Physician’s practice patterns, Survival
analysis
Background
Drugs are an essential part of medical practice and
represent a high economic burden. The pattern of pre-
scription varies among physicians and many influences
on the doctor’s prescription other than the clinical indi-
cations have been described [1-3]. In this context, the
introduction and diffusion of new drugs on the market
is an issue of special transcendence. The diffusion of a
new drug can be defined as its dissemination through
different channels over time among physicians [4].
The substitution of established therapies for new
drugs is often inappropriate because of lack of improve-
ments in effectiveness, when unknown side effects can-
not be ruled out at the time of marketing [5] and the
prices are disproportionate to the alleged benefits [6,7].
However, a delayed uptake of effective innovations sup-
ported by clinical investigation has also been observed,
resulting in non-optimal treatments for some patients
[8].
There is a substantial difference in prescribing a new
drug for the first time ever and to prescribe it routinely
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any medium, provided the original work is properly cited.[9]. A physician is an adopter of a new drug if he incor-
porates it to his personal formulary and hence pre-
scribes it regularly.
Our study aims to analyze the diffusion of eight new
drugs during the first months of use and examine the
differences in the adoption of these new drugs between
family physicians and specialists. We focus in adopters
because we are interested in doctors who have changed
their prescribing behaviour. The dynamics of this pro-
cess is important to design educational or administrative
activities.
Even though this study cannot identify all the factors
that influence the diffusion of these drugs, it may be
useful for generating hypothesis about the characteristics
of the drugs that influence its diffusion and the relation-
ship with the medical specialty. All this information
c o u l db eu s e df o re s t a b l i s h i ng the timing of dissemina-
tion of scientific information on new drugs and for iden-
tifying sectors of doctors where a special attention
would be required.
Methods
We performed a retrospective study with the prescrip-
tion database of the Navarre Health Service (Servicio
Navarro de Salud - Osasunbidea,S N S - O )u s i n gd a t a
from 2003 to 2007. This database includes monthly
information of all prescriptions financed by the SNS-
O. By Spanish law, the aggregate information resulting
from processing prescriptions of the National Health
System is of public domain and its evaluation is com-
petence of health services [10]. In Navarre the task
belongs to the Pharmaceutical Benefits Service (Servi-
cio de Prestaciones Farmacéuticas), which is part of the
SNS-O. The Pharmaceutical Benefits Service provides
feed back information to doctors about the use of new
medicines, so the name of the doctor is included in
the database.
Ethics statement: The study was approved by the
scientific council of the Health Department of the Gov-
ernment of Navarre. We used a database that did not
include patient information. Therefore, no ethical
approval was necessary.
The SNS-O provides tax-financed health care in
Navarre (Spain) and it covers pharmaceutical benefits to
approximately 600,000 persons (95% of the population).
Doctors working for the SNS-O are employees of it. All
of them work in group practices or in hospitals. Specia-
lists normally write the first prescription of the drug
they indicate.
From the drugs marketed between 2003 and 2007,
eight drugs with different indications were chosen
(Table 1). All of them are suitable for use both at pri-
mary and at secondary care levels and were indicated in
common disorders in clinical practice. During the study
period those drugs were the latest licensed of their ther-
apeutic group for their indications. The Drug Assess-
ment Working Group of the SNS-O evaluates the
degree of therapeutic innovation of the new drugs and
provides drug assessment reports to the doctors belong-
ing to the SNS-O. The degree of therapeutic innovation
of each new drug is determined in accordance with cri-
teria of level of evidence, efficiency, safety, convenience
and cost, all in comparison with alternative therapies.
In the case of etoricoxib, a prior authorization was
required for its prescription at the onset of marketing.
This requirement was withdrawn 24 month after its
launching.
For each drug, the month in which the first prescrip-
tion was issued was considered month 1 and a follow
up of the drug prescription was carried out for a period
of up to 36 months.
Doctors who had signed some prescription in 2003
and also in 2007 were eligible.
We select those who prescribed any of the eight stu-
died drugs. From this group we analyzed the number of
prescriptions per physician at months 2, 3, 6, 12, 24 and
36 in family physicians.
To define the group of adopters of a drug, we first
excluded those physicians who prescribed it sporadically
(less than 10 prescriptions during the 36 month study
period). Then for each drug and level (primary care or
secondary care) we selected physicians whose number of
prescriptions was over the 25th percentile of prescrip-
tions per drug and physician within each level. Using
this criterion we deal with the differences in the number
of patients, contacts and case-mix.
The diffusion of each drug was studied among the
group of adopter physicians. The adoption time of a
drug was defined as the month in which the physician
makes the first prescription. We plotted the curve of
cumulative number of adopter primary care physicians
over time after the launching of the drug. A Kaplan-
Meier survival analysis was performed with the adop-
tion time. The log rank test was used to test differ-
ences between family physicians and the different
specialists. Statistical analysis was performed using the
program PASW Statistics
® for Windows (version 17.0,
SPSS Inc.).
Results
Of 1248 physicians with a prescription, 904 prescribed
some of the selected drugs and 441 were considered as
adopters (Figure 1).
Prescribing family physicians and mean of prescriptions
Table 2 shows the number of family physicians who
have prescribed each studied drug and the mean of pre-
scriptions per physician at different times.
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specialty
The diffusion of drugs among adopter family physicians
is presented in Figure 2.
The adoption of the new drugs under study in primary
care shows a similar pattern, represented by an exponen-
tial diffusion curve [11]. In the first months after the
launching of the drug, the number of adopters increased
rapidly to finally reach a plateau. Curves show different
slopes (speed of adoption) and different heights (number
of doctors who eventually adopted the drugs). The curves
reach plateaus in different months, between 6 and 23,
reflecting different rates of diffusion of the drugs.
Tiotropium was the most rapidly disseminated and
most widely adopted drug. Cefditoren spread at the
slowest rate and was the least adopted. Etoricoxib was
an exception because it did not reach a plateau during
the study period.
The differences between specialties in adoption of the
drugs under study are shown in Table 3. Although each
drug is prescribed by several specialties, the proportion
of adopters is very different. For each drug there is one
specialty that adopted it before family physicians and
with a percentage of adopters of at least 50%: otolaryn-
gology for cefditoren, psychiatry for duloxetine, rheuma-
tology for etoricoxib, endocrinology for ezetimibe,
allergology for levocetirizine, rheumatology for pregaba-
lin and pneumology for tiotropium. Olmesartan was an
exception since the percentage of family physician adop-
ters was far larger than specialists although cardiology
adopted it faster.
Discussion
The adoption of new drugs in primary care follows an
exponential curve. In consumer research, this shape
indicates consumers perceive little risk (physical or eco-
nomic) associated with the innovation [11]. We believe
this perception is not desirable in the field of new drugs.
Table 1 Characteristics of the studied drugs
Drug Launching Degree of
therapeutic
Innovation*
Approved indications Cost/
DDD
Alternatives (cost/DDD)
Cefditoren Sep-04 No therapeutic
innovation
Pneumonia, exacerbation of chronic bronchitis,
pharyngitis, tonsillitis, skin infections
€4.47
-6.26
Amoxicillin-clavulanate (€0.68)
Cefuroxime axetil (€2.27)
Duloxetine Dec-05 No therapeutic
innovation
Neuropathic pain, depresión, generalised anxiety disorder
(from jul-08)
€1.99 Amitriptyline (€0.11)
Fluoxetine (€0.24)
Paroxetine (€0.79)
Etoricoxib Jul-04 No therapeutic
innovation
Osteoarthritis, rheumatoid artritis, acute gouty artritis,
ankylosing spondylitis (from sep-08)
€1.74 Ibuprofen (€0.24)
Diclofenac (€0.17)
Naproxen (€0.38)
Ezetimibe Mar-04 Insufficient evidence Primary hypercholesterolaemia, homozygous familial
hypercholesterolaemia, homozygous sitosterolaemia
€1.91
Levocetirizine Apr-03 No therapeutic
innovation
Allergic rhinitis, chronic idiopathic urticaria €0.56 Cetirizine (€0.29)
Olmesartan May-04 No therapeutic
innovation
Hypertension €0.92 Losartan (€0.92) Enalapril
(€0.13)
Pregabalin Jan-05 No therapeutic
innovation
Neuropathic pain, epilepsy, generalised anxiety disorder
(from mar-06)
€2.57 Gabapentin (€0.19)
Amitriptyline (€0.11)
Tiotropium Jan-03 Modest therapeutic
innovation
Chronic obstructive pulmonary disease €1.91 Ipratropium (€0.28)
*No therapeutic innovation: The new drug has no added value over other drugs which are already available in the market for the same indication. Modest
therapeutic innovation: The new drug provides more posology comfort. Insufficient evidence: Available evidence is insufficient or inconclusive, or lacks good
quality clinical trials including an adequate comparative drug.
DDD defined daily dose.
Information provided in the reports of the Navarre Drug Assessment Working Group [Available in: http://www.navarra.es/home_es/Temas/Portal+de+la+Salud/
Profesionales/Documentacion+y+publicaciones/Publicaciones+tematicas/Medicamento/BIT/].
1248 physicians with any prescription in 2003 and also in 2007 
 
938 specialists 
310 family physicians 
904 physicians who had prescribed any studied drug in the first 36 
months of marketing 
 
598 specialists 
306 family physicians 
441 adopter physicians of any studied drug 
 
189 specialists 
253 family physicians 
Figure 1 Flow diagram.
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by several factors apart from how effectively it is
marketed.
Degree of therapeutic innovation
It is determined in accordance with criteria of evidence,
efficiency, safety, convenience and cost, all in
comparison with alternative therapies. Tiotropium was
the most widely and quickest adopted drug by family
physicians. It was the only studied drug that was rated
as a therapeutic innovation but we cannot affirm that it
is the main reason for its rapid diffusion. In the litera-
ture, however, this quality is not related consistently
with adoption [12,13]. Personal perceptions about
Table 2 Family physicians who prescribe each drug at different times and mean prescriptions per physician
Month since launching
23 6 1 2 2 4 3 6
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Cefditoren 7 3.6 (4.2) 26 2.3 (1.9) 30 3.4 (2.8) 32 3.3 (5.7) 44 2.0 (2.2) 51 2.6 (2.8)
Duloxetine 38 1.5 (0.9) 67 2.0 (1.5) 125 2.4 (2.0) 172 3.5 (2.7) 176 5.1 (3.8) **
Etoricoxib 14 1.1 (0.4) 32 1.6 (0.9) 41 1.4 (0.6) 44 1.5 (0.8) 48 1.9 (1.3) 124 3.1 (4.0)
Ezetimibe 31 2.0 (1.4) 59 2.0 (1.5) 94 2.3 (1.9) 148 2.7 (2.5) 200 4.0 (3.6) 191 4.6 (3.8)
Levocetirizine 8 1.6 (0.9) 9 1.6 (0.7) 21 1.2 (0.4) 75 2.2 (1.6) 132 2.4 (1.7) 158 3.0 (2.8)
Olmesartan 36 1.8 (1.0) 49 2.2 (1.3) 89 2.3 (1.7) 131 3.4 (3.7) 165 4.1 (4.8) 182 4.7 (5.5)
Pregabalin 14 1.3 (0.5) 31 1.7 (1.4) 80 1.8 (1.0) 137 2.3 (1.8) 181 3.7 (2.7) 198 5.1 (3.6)
Tiotropium 80 2.3 (1.6) 127 2.9 (2.4) 215 3.5 (2.6) 244 5.9 (4.0) 264 7.4 (4.9) 264 8.5 (5.4)
n number of physicians. SD standard deviation.
*Data of 36
th month of duloxetine are no comparable due to changes in medical staff.
Month after launching
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Figure 2 Cumulative number of adopter family physicians who prescribe each drug over time.
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tives are consistent factors that influence the decision to
adopt a drug [14,15]. Cost does not seem to be a deter-
mining factor [3,16].
Me-too drugs
They are drugs chemically related with a previous
approved drug, with the same mechanism of action and
indications. Since there is a perception of well known
drugs, its adoption can be facilitated. On the other
hand, there are few reasons for adopting them due to
their scarce therapeutic advantages. Olmesartan belongs
to a commonly used class of drugs, angiotensin II recep-
tor blockers, employed in the management of hyperten-
s i o n .A l t h o u g hi tw a sn o tm assively adopted, the
percentage of adopters was greater for family physicians
than for specialists. It can be explained by their indica-
tion which is managed almost entirely in primary care.
Levocetirizine, a isomer of cetirizine, is an example of
strategy to prolong the life of drug when the patent
expires in the face of competition from generic drugs
[17].
Table 3 Adopters per drug and specialty and time of adoption
Time of adoption
Drug Specialty Number of prescribers Number of adopters (%) Median in months (intercuartile range) Comparison
with Family
Physicians.
Log-rank test
c
2 p-value
Cefditoren Otolaryngology 19 11 (58%) 2 (2-5) 6.76 0.01
Family physicians 232 50 (22%) 4 (3-7)
Internal medicine 22 4 (18%) 5 (3-10) 0.44 NS
Emergencies 65 7 (11%) 9 (5-21) 6.39 0.01
Pneumology 15 7 (47%) 9 (8-12) 1.14 NS
Duloxetine Psychiatry 36 22 (61%) 2 (2-3) 29.55 < 0.01
Family physicians 252 160 (63%) 4 (3-6)
Etoricoxib Rheumatology 6 3 (50%) 2 (1-8) 8.08 < 0.01
Traumatology 55 21 (38%) 3 (2-15) 1.97 NS
Family physicians 230 105 (46%) 10 (3-20)
Rehabilitation 14 2 (14%) 11 (11-26) 0.51 NS
Ezetimibe Cardiology 16 6 (38%) 2 (1-3) 8.13 < 0.01
Endocrinology 11 8 (73%) 3 (2-3) 10.95 < 0.01
Family physicians 258 168 (65%) 5 (3-8)
Levocetirizine Otolaryngology 19 8 (42%) 1 (1-4) 24.14 < 0.01
Allergology 10 10 (100%) 4 (2-7) 4.96 0.03
Emergencies 44 4 (9%) 4 (4-12) 0.73 NS
Dermatology 15 12 (80%) 9 (2-12) 1.54 NS
Family physicians 264 141 (53%) 10 (7-13)
Olmesartan Cardiology 15 3 (20%) 1 (1-2) 17.23 < 0.01
Internal medicine 21 3 (14%) 2 (2-13) 0.04 NS
Family physicians 256 154 (60%) 6 (3-9)
Pregabalin Anesthesiology 8 3 (38%) 2 (2-5) 8.45 < 0.01
Neurology 17 8 (47%) 3 (2-4) 12.1 < 0.01
Rheumatology 6 6 (100%) 3 (2-4) 9.83 < 0.01
Rehabilitation 23 17 (74%) 5 (2-7) 2.94 NS
Family physicians 275 180 (65%) 6 (4-10)
Traumatology 56 17 (30%) 6 (4-9) 0.87 NS
Tiotropium Pneumology 15 14 (93%) 1 (1-2) 49.18 < 0.01
Internal medicine 30 14 (47%) 2 (2-5) 0.13 NS
Family physicians 297 207 (70%) 3 (2-4)
NS: p > 0.05
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Doctors are likely to prescribe drugs with a new
mechanism of action [3]. Ezetimibe has the same indica-
tions than effective therapies like statins; but its
mechanism of action is different. The decreasing lipid
targets in guidelines may have promoted its adoption as
add-on therapy.
Range of indications
Pregabalin was adopted initially at a not very fast rate,
b u ta tt h ee n do ft h es t u d yp e r i o dw a sa d o p t e db ya
l a r g en u m b e ro fp h y s i c i a n s .T h i sm a yb eb e c a u s et h e
range of its indications was increased. Besides, pregaba-
lin is indicated for diseases with a poor response to
therapies like neuropathic pain or generalised anxiety
disorder.
Duloxetine has the indication of depression, a very
common condition that explains the wide adoption for
psychiatrists and for family physicians. Surprisingly,
although it is also indicated in neuropathic pain, in con-
t r a s tw i t hp r e g a b a l i n ,i tw a sn o ta d o p t e db yt h es p e c i a l -
ties that deal with this disease (anaesthesiology,
neurology and rheumatology).
Policies
Cefditoren had the lower number of adopters in primary
care. The policy of rational use of antibiotics may have
limited its utilization.
Etoricoxib initially required an endorsement before
dispensation, which was subsequently withdrawn allow-
ing for wider prescription henceforth. The effect of an
authorization requirement for COX-2 inhibitor drugs
has been determined in the U.S.A [18].
Chronic versus acute use
Due to the use of ceftditoren in acute diseases, there is
not induced prescription (treatment initiated in second-
ary care and followed in primary care). This can have
contributed to its low adoption.
The seasonal use of levocetirizine can be responsible
for its long adoption time.
The results from this study suggest that secondary
care plays a key role in the adoption of new drugs by
family physicians. Drugs are adopted earlier by specia-
lists. This fact could be justified when the drugs are
indicated in a disease managed mainly by specialists.
The early adopter role of the specialists may be due to
various factors: differences in sources of information
[3,16], differences in the attitude towards evidence-
based medicine [19] and differences in the tolerance to
uncertainty [20].
Specialists’ prescription influence family physicians by
induced or imitated prescriptions [3,21]. Our study can
not differentiate between prescriptions originating from
primary care and induced.
Why some specialties have a low percentage of adop-
ters, even lower than family physicians? Specialists
always choose the drugs they use. However, the family
physician often follows the prescriptions of the specia-
lists. Another reason can be the existence of sub-special-
ties (e.g. a neurologist who treats mainly Parkinson
disease can use few antiepileptic drugs).
This study focuses on adopters because our interest is
the process of inclusion of a drug in the therapeutic
arsenal of physicians and not the occasional prescrip-
tion. The definition of an adopter of a new drug was ad
hoc. We do not categorise physicians as early or late
adopters, as is common in the literature about diffusion
of new drugs [4,12,22]. The notion that early adoption
is a personal characteristic has been challenged [9].
We use time-to-event analysis to compare adoption
times between primary and secondary care. We find this
model useful to describe the process of adoption
because time is a key variable for designing intervention
strategies. Another study used a Cox model to compare
single-handed to partnership practices [9].
This study has several limitations. The analysis is lim-
ited to eight drugs and the results may not be general-
ized. We could not differentiate between prescriptions
originating from primary care and those induced.
The median time of adoption for family physicians is
between 4 and 6 months for the majority of the drugs.
This period is shorter for specialists. New drugs are
adopted before safety and cost-effectiveness are well
established. At the time a new drug reaches the market,
information about its efficacy and safety came only from
clinical trials. Generally, they are too short, with too few
patients and too narrow. Only selected patients are
included. Those older, non compliant, with polyphar-
macy or with multiple pathologies are often excluded.
This makes impossible the accurate identification of
adverse effects. The selection of patients in clinical trials
and the reliance in subrogate end points prevent from
establishing the effectiveness in real life situations and
hence the cost- effectiveness.
“D oN o tR u s ht oU s eN e w l yM a r k e t e dD r u g s ” has
been proposed as a principle of judicious prescribing.
Older drugs are generally safer owing to their longer
track record. Even, to wait 7 years before using a new
drug has been advocated, based on data showing that it
often takes 5 to 10 years to identify significant adverse
effects [23]. This is in great contrast with the adoption
rate in our study.
New drugs often replace others better known and
cheaper. The short period of adoption should be taken
into account if we consider the implementation of
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drug (e.g. independent drug information or medical edu-
cation activities). Albeit there is a large room for
improvement in drug regulatory agencies [23], health
systems have the responsibility to design strategies to
promote the cautious adoption of innovative drugs; inhi-
bit the adoption of the non-innovative ones; and avoid
the premature abandonment of established therapies. If
there is a risk of a delayed introduction of truly innova-
tive products has to be balanced against the risk of
treating patients with a drug before its safety was well
established.
Ideally, information about the relative efficacy and
safety of a new drug should be known before launching
or at least before being adopted. This information has to
be evidence-based and independent of the pharmaceuti-
cal industry. Drug bulletins publish reviews of new drugs
trying to help their readers recognise the products that
really are an advance and which deserve to be included
in the list of drugs they use. Outreach visits, continuing
education meetings and workshops are also used. All
those instruments show limited effectiveness. Multifa-
ceted interventions are more effective than simply deli-
vering information [24].. It is necessary to consider that
interventions are often carried out against aggressive
marketing campaigns of the pharmaceutical industry that
can promote inappropriate prescription [25]. Therefore,
it should be recognised that modifying prescribing beha-
viour is difficult. The design of interventions should have
a wider scope taking into account the attitudes and
beliefs of doctors, and the existence of professional net-
works both formal and informal [3,16,19]. The imposi-
tion of administrative requirements could be effective.
It is necessary to explore the influence of factors such
as the relationship with the pharmaceutical industry,
continuing education and independent drug informa-
tion. Moreover, the identification of other factors could
help explain the dynamics of new drugs adoption in
order to design better strategies for promoting the selec-
tion of cost-effective therapies.
Conclusions
The number of adopters of a new drug increases quickly
in the first months and reaches a plateau. The number
of adopter family physicians varies considerably for dif-
ferent drugs. The adoption of new drugs is faster in spe-
cialists. The time of adoption should be considered to
promote rational prescribing by providing timely infor-
mation about new drugs and independent medical
education.
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